Stocktoria
GSK plc GSK.L
GB · London Stock Exchange · XLON · stock · Healthcare · website
GSK plc financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $32.7B | $31.4B | $30.3B | $29.3B |
| Gross profit | $23.6B | $22.3B | $21.8B | $19.8B |
| R&D expense | $7.5B | $6.4B | $6.2B | $5.5B |
| SG&A expense | $9.1B | $11.0B | $9.4B | $8.4B |
| Operating income | $8.3B | $5.5B | $7.3B | $6.7B |
| Interest expense | $687.0M | $640.0M | $725.0M | $826.0M |
| Income tax | $1.1B | $526.0M | $756.0M | $707.0M |
| Net income | $5.7B | $2.6B | $4.9B | $15.0B |
| EPS (diluted) | $1.39 | $0.62 | $1.20 | $3.66 |
| Operating cash flow | $7.7B | $6.6B | $6.8B | $7.4B |
| Free cash flow | $4.8B | $3.6B | $4.4B | $5.1B |
| Cash & equivalents | $3.1B | $3.7B | $2.7B | $3.5B |
| Inventory | $5.9B | $5.7B | $5.5B | $5.1B |
| Total assets | $61.1B | $59.5B | $59.0B | $60.1B |
| Total liabilities | $45.2B | $46.4B | $46.2B | $50.0B |
| Shareholders' equity | $16.4B | $13.7B | $13.3B | $10.6B |
Growth · year-over-year · Revenue CAGR 3.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +4.1% | +3.5% | +3.4% | — |
| Net income growth | +122.0% | -47.7% | -67.1% | — |
| EPS growth | +123.2% | -48.1% | -67.3% | — |
| Free cash flow growth | +33.1% | -19.3% | -14.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.